<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic. The immunotherapy with monoclonal antibodies, adoptive cell therapy and checkpoint inhibition are discussed. The commonly used monoclonal antibodies are Trastuzumab targeting HER2 and Bevacizumab suppressing VEGF and tumor angiogenesis. Treatment with tumor-specific T cells is called adoptive cell therapy. There is experience with the application of tumor infiltrating lymphocytes (TILs), cytotoxic T lymphocytes (CTLs) and cytokine-induced killer cells (CIK). This review discusses the therapy with innate immune cells with anti-tumor activity such as dendritic cells and NK cells. The checkpoint inhibition was also reviewed. In conclusion, it could be stated that the immunotherapy of GC has the potential to provide a more favorable outcome to patients with GC, but it also have some limitations which need to be considered.</p></abstract>

Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA hypermethylation. Therefore, GC is more immunogenic. The immunotherapy with monoclonal antibodies, adoptive cell therapy and checkpoint inhibition are discussed. The commonly used monoclonal antibodies are Trastuzumab targeting HER2 and Bevacizumab suppressing VEGF and tumor angiogenesis. Treatment with tumor-specific T cells is called adoptive cell therapy. There is experience with the application of tumor infiltrating lymphocytes (TILs), cytotoxic T lymphocytes (CTLs) and cytokine-induced killer cells (CIK). This review discusses the therapy with innate immune cells with anti-tumor activity such as dendritic cells and NK cells. The checkpoint inhibition was also reviewed. In conclusion, it could be stated that the immunotherapy of GC has the potential to provide a more favorable outcome to patients with GC, but it also have some limitations which need to be considered.

Novel Immunotherapeutic Approach in Gastric Cancer

Department of General and Clinical Pathology, Medical Faculty

Acta Medica Bulgarica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

In Memory of My Close Friend Stefan Lazarov, Who Suffered from Gastric Cancer and Was Cured with CIK

Gastric cancer (GC) is suitable for immunotherapy because 80% of it display microsatellite and chromosomal instability, some mutations and DNA...

Novel Immunotherapeutic Approach in Gastric Cancer

Publié en ligne: 27 juil. 2020

Pages: 47 - 54

Reçu: 01 août 2019

Accepté: 01 oct. 2019

DOI: https://doi.org/10.2478/amb-2020-0024

Mots clés
gastric cancer, immunotherapy, antibodies, cell therapy

© 2020 M. Gulubova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Novel Immunotherapeutic Approach in Gastric Cancer

Publié en ligne: 27 juil. 2020

Pages: 47 - 54

Reçu: 01 août 2019

Accepté: 01 oct. 2019

DOI: https://doi.org/10.2478/amb-2020-0024

Mots clésgastric cancer, immunotherapy, antibodies, cell therapy

© 2020 M. Gulubova et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mots clés
gastric cancer, immunotherapy, antibodies, cell therapy